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Abstract
Background: Measuring the effects of the acute intake of natural products on human biomarker concentrations,
such as those related to oxidation and inflammation, can be an advantageous strategy for early clinical research on
an ingredient or product.
Methods: 31 total healthy subjects were randomized in a double-blinded, placebo-controlled, acute pilot study
with post-hoc subgroup analysis on 20 of the subjects. The study examined the effects of a single dose of a
polyphenol-rich beverage (PRB), commercially marketed as “SoZo
®”, on serum anti-inflammatory and antioxidant
markers. In addition, phytochemical analyses of PRB, and in vitro antioxidant capacity were also performed.
Results: At 1 hour post-intake, serum values for 8-iso-PGF2-alpha and advanced oxidation protein products
decreased significantly by 40% and 39%, respectively. Additionally, there was a trend toward decreased C-reactive
protein, and increased nitric oxide levels. Both placebo and PRB treatment resulted in statistically significant
increases in hydroxyl radical antioxidant capacity (HORAC) compared to baseline; PRB showed a higher percent
change (55-75% versus 23-74% in placebo group), but the two groups did not differ significantly from each other.
Conclusions: PRB produced statistically significant changes in several blood biomarkers related to antioxidant/anti-
inflammatory effects. Future studies are justified to verify results and test for cumulative effects of repeated intakes
of PRB. The study demonstrates the potential utility of acute biomarker measurements for evaluating antioxidant/
anti-inflammatory effects of natural products.
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1. Introduction
Inflammation is associated with and/or implicated in
numerous disease states, such as metabolic syndrome,
coronary artery disease, diabetes, erectile dysfunction,
arthritis, obesity and cancer [1-3]. While inflammation
serves as a normal and necessary response to tissue
injury and infections, excessive inflammation can be
pathological. Dietary components have the potential to
modulate inflammatory conditions and play a role in the
prevention and/or treatment of disease states [4].
Intake of plant polyphenol-containing foods and pro-
ducts has been associated with beneficial levels of anti-
oxidant/anti-inflammatory markers, and health
promoting effects in epidemiological, in vitro, ex vivo
and in vivo studies [4-8]. It is not always clear whether
direct, rapid antioxidant/anti-inflammatory effects, or
longer-term regulatory actions are responsible. For
example, high isoflavone soy protein intake over 4
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on a total antioxidant status assay; yet adding isofla-
vones in vitro to plasma pooled from subjects samples
drawn prior to treatment had little effect [9]. The latter
lack of effect occurred even if isoflavones were added
well in excess of what oral intake could produce in
serum samples. Similarly, a 4-week intake of an isofla-
vone concentrate can raise erythrocyte contents of the
antioxidant enzyme superoxide dismutase 1, but this
effect would not be expected to occur immediately after
a single intake of isoflavones [10].
In 2001, a NIH working group standardized the defini-
tion of a biomarker as “a characteristic that is objectively
measured and evaluated as an indicator of normal biolo-
gical or pathogenic processes, or pharmacologic
responses to a therapeutic intervention” [11]. Biomar-
kers can indicate a variety of health or disease character-
istics including responses to various types of
interventions such as diet, nutrients, or therapeutics. A
biomarker can be classified as a surrogate end-point bio-
marker (i.e., a marker that is intended to substitute for a
clinical end point). Generally, a surrogate end point is
expected to predict clinical benefit, harm, or lack
thereof, on the basis of epidemiological, therapeutic,
pathophysiological, or other scientific evidence [12].
Biomarker measurements allow investigation of food
and nutritional products in human subjects over a
shorter time course as compared to following gross clin-
ical endpoints such as disease occurrence or symptom
progression. It also allows researchers to avoid data
interpretation and compliance-issues often associated
with longer studies.
The present study examines the effect of short-term
consumption of a polyphenol-rich beverage (PRB) on
several biomarkers related to antioxidant/anti-inflamma-
tory processes. The PRB utilized in this study is called
SoZo
®, and contains numerous fruit and vegetable
extracts that are described in detail in the materials and
methods section. It includes coffee fruit extract as the
first listed ingredient, which is rich in polyphenolic com-
pounds [13,14]. The serum biomarkers that were fol-
lowed during the study include 8-iso-PGF2-alpha,
advanced oxidation protein products (AOPP), nitric
oxide (NO), C-reactive protein (CRP) and the hydroxyl
radical antioxidant capacity (HORAC) assay. These mar-
kers are further described below.
8-iso-PGF2-alpha is an isoprostane derived from ara-
chidonic acid via lipid peroxidation in vivo.I ti sa
potent vasoconstrictor, and is considered a gold stan-
dard for measuring oxidative stress in vivo [15-17]. Stu-
dies have shown that serum levels of this biomarker are
raised under certain inflammatory conditions such as
obesity, diabetes, arthritic and cardiovascular diseases
[15,18-21].
AOPPs are the products of plasma protein oxidation–
especially oxidation of albumin. Because of its rapid
response to changes, it is thought to be suitable for
measuring short-term changes in oxidative stress [22].
Serum levels are increased in subjects with inflammatory
conditions such as ulcerative colitis, ankylosing spondy-
litis and renal failure [23,24]. Increased AOPP levels also
correlate with cardiovascular disease markers–they may
have a causal relationship in the development of athero-
sclerosis, as has been shown in rabbits [25].
Nitric oxide (NO) is a ubiquitous compound in the
body that plays an important role in vasodilation via the
relaxation of vascular smooth muscle, and hence in
increasing circulation in the body. It also inhibits plate-
let aggregation and leukocyte activation. A number of
plant polyphenolic compounds have been shown to
modulate NO levels and/or actions [26,27].
CRP is an acute phase protein that is produced mainly
by hepatocytes in response to inflammatory cytokines in
the body, and is hypothesized to serve as a marker of
cardiovascular disease risk. Increased levels also corre-
late with type II diabetes, obesity and smoking [3,28]. It
is present at very low levels in healthy individuals, and
an increased intake of foods rich in polyphenolic com-
pounds is inversely associated with serum CRP concen-
trations [3,29,30].
This acute single-dose investigational pilot study
assesses changes in blood levels of targeted biomarkers
indicative of antioxidant capacity, oxidative stress, and
inflammation. The approach provides rapid results after
the treatment of human subjects with tested material in
comparison to placebo.
2. Materials and Methods
2.1 PRB Composition
T h ed e s i g na n df o r m u l a t i o no ft h ep o l y p h e n o l - r i c h
SoZo
® beverage (PRB) was based upon a rational exami-
nation of existing scientific information regarding poten-
tial health benefits of the individual ingredients. The
PRB consists of two major components:
1. 1.) A proprietary, powdered blend of selected freeze-
dried whole fruit and vegetable powders, concentrated
plant phytonutrients, and fruit and vegetable extracts
consisting of: whole coffee fruit extract (CoffeeBerry
®),
Coffea arabica; calcium fructoborate (FruiteX B
®), a
patented plant-mineral complex; grape seed, Vitis vini-
fera; North American wild blueberry, Vaccinium augusti-
folium;q u e r c e t i n ,Sophora japonia L; resveratrol,
Polygonum cuspidatum;b i l b e r r y ,Vaccinium myrtillus L;
raspberry, Rubus idaeus; cranberry, Vaccinium macrocar-
pon;p r u n e ,Prunus domestica; tart cherry, Prunus cera-
sus; strawberry, Fragaria chiloensis; grape seed extract,
Vitis vinifera; broccoli sprouts, Brassica oleraca italica;
broccoli, Brassica oleraca italica; tomato, Lycopersicon
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cea oleracea; kale, Brassica oleracea acephala;b r u s s e l s
sprout, Brassica oleracea gemmifera;p o m e g r a n a t e
extract, Punica granatum; and acai pulp, Euterpe olera-
cea. All components of the powdered blend were sup-
plied by FutureCeuticals, Inc. (Momence, IL).
2. 2.) A preservative-free liquid delivery system used to
dissolve the previously described powder mixture. This
liquid consisted of a blend of juices of grape, Vitis vini-
fera;p o m e g r a n a t e ,Punica granatum;p e a r ,Pyrus com-
munis; apple, Pyrus malus; strawberry, Fragaria
chiloensis; acai, Euterpe oleracea;y u m b e r r y ,Myrica
rubra;c u p u a c u ,Theobroma grandiflorum;a n dc a m u
camu, Mycaria dubia;a sw e l la sS e n s o r i l ™ (a standar-
dized extract of Ashwagandha (Withania somnifera);
and natural flavors and colors.
2.2 Phytochemical Analysis
2.2.1 Ellagic acid content
The sample was analyzed with an HPLC Agilent 1100
(Agilent Technologies, Palo Alto, CA) equipped with
diode array detector. Ellagic acid was detected at 254
nm. Separations were done on a 4.6 X 250-mm C-18
reversed-phase column Waters SymmetryShield RP18
(Milford, MA) containing particles with a size of 5 μm.
T h em o b i l ep h a s e sw e r e0 . 1 %p e r c h l o r i ca c i d( m o b i l e
phase A) and methanol (mobile phase B). The gradient
system began with 50% of the mobile phase A and 50%
of the mobile phase B, and was changed to 88% mobile
phase B linearly after 20 minutes. After 40 minutes, the
column was re-equilibrated to the starting conditions.
The retention time of ellagic acid at a flow rate of 1
mL/min was 19.059 min as determined by co-injection
with an ellagic acid standard (PhytoLab, Vestenbergs-
greuth, Germany).
2.2.2 Total polyphenol content
Total polyphenol content was determined by spectro-
photometry according to the Folin-Ciocalteu method,
and was calibrated against gallic acid standard (Sigma-
A l d r i c h ,S t .L o u i s ,M O ) .R e s u l t sw e r ee x p r e s s e da s
grams of gallic acid equivalents [31].
2.2.3 Total anthocyanin content
Total anthocyanin content was determined by UV-vis
spectrophotometry, using malvidin 3-glucosinolate (Phy-
toLab, Vestenbergsgreuth, Germany) as an external stan-
dard. 2% methanolic HCl solution was used for
anthocyanins extraction. Samples were sonicated at 50°C
for five minutes and shaken vigorously for 30 seconds.
The absorbance was read at 535 nm. The amount of
total anthocyanins was calculated as malvidin 3-gluco-
side equivalents.
2.2.4 Chlorogenic acid content
Chlorogenic acid content was determined by UV-vis
spectrophotometry Shimadzu 1650PC (Kyoto, Japan) at
325 nm. Samples were prepared using 50% methanol/
water solution and sonicated for 5 minutes. Chlorogenic
acid from USP was used as an external standard.
2.2.5 Proanthocyanidin content
Proanthocyanidin content was determined using vali-
dated dimethylaminocinnamaldehyde colorimetric
method [32] originally modified by Brunswick Labs
(Norton, MA) using a commercially available A2 dimer
standard (HPLC grade; purity >99%; Extrasynthese,
France; Cat. # 0985 S).
2.3 Antioxidant Analysis
2.3.1 Hydrophilic Oxygen Radical Absorbance Capacity
(ORAC) assay
Hydrophilic ORAC assay was performed according to
t h em e t h o do fO ue ta l[ 3 3 ] .T h ea r e au n d e rt h ec u r v e
(AUC) was calculated by integrating the relative fluores-
cence curve. The net AUC of the sample was calculated
by subtracting the AUC of the blank. The regression
equation between net AUC and Trolox concentration
was determined, and ORAC values are expressed as
μmol Trolox equivalents (TE) per gram.
2.3.2 Hydroxyl radical antioxidant capacity (HORAC) assay
The HORAC assay was based on a previously reported
method [33] modified for the FL600 micro plate fluores-
cence reader (Bio Tek Instruments, Inc. Winooski, VT).
Fluorescein (FL) was used as the probe. The fluores-
cence decay curve of FL is monitored in the absence or
presence of antioxidants, the area under the fluores-
cence decay curve (AUC) is then integrated, and the net
AUC is calculated by subtracting the AUC of the blank
from that of the sample antioxidant.
2.3.3 Peroxynitrite radical absorbance capacity (NORAC)
assay
The NORAC assay was performed by a modified method
[33,34]. Briefly, a stock solution of DHR-123 (5 mM) in
dimethylformamide was purged with nitrogen and stored
at -80 °C. A working solution with DHR-123 (f.c. 5 M)
diluted from the stock solution was placed on ice in the
dark immediately prior to the study. Peroxynitrite
scavenging by the oxidation of DHR 123 was measured
with a FL 600 microplate fluorescence reader (Bio Tek
Instruments, Winooski, VT) with excitation and emission
wavelengths of 485 and 530 nm, respectively, at room
temperature. The background and final fluorescent inten-
sities were measured 5 minutes after treatment with or
without SIN-1 (f.c. 10 M) or authentic peroxynitrite (f.c.
10 M) in 0.3 N sodium hydroxide. Oxidation of DHR-
123 by decomposition of SIN-1 gradually increased,
whereas authentic ONOO- rapidly oxidized DHR-123
with its final fluorescent intensity being stable over time.
2.3.4 Singlet oxygen absorbance capacity (SOAC) assay
Singlet oxygen was generated in ethanol by the molyb-
date-catalyzed disproportionation of hydrogen peroxide
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singlet oxygen. Hydroethidine was prepared in N,N-
dimethylacetamide (DMA) to make 40 M solution,
2.635 mM Na2MoO4 and 13.125 mM H2O2 working
solutions were also prepared in DMA. 125 L of HE solu-
tion was added to a well followed by addition of 25 L
2.635 mM Na2MoO4
2- and 25 L 13.125 mM H2O2 ,
respectively.
2.4 Clinical Study
The clinical pilot study protocol (FC-NC-0902) was
approved by the Institutional Review Board at Vita Clin-
ical SA, Avenida Circunvalacion Norte #135, Guadala-
jara, JAL, Mexico 44270. Males and females between the
ages of 45-55 years, with a BMI of 25-36 were recruited
for the study. Other inclusion criterion included: sub-
jects otherwise reported themselves as “healthy” (no
known disease conditions), were not on any medica-
tions, were not allergic to fruits and were not experien-
cing any digestive problems. A total of 31 subjects were
randomized into two groups; a PRB and placebo group.
PRB and placebo samples were prepared in coded
tubes and refrigerated at approximately 1.5-3.5°C until
time of serving. PRB samples were obtained from a
commercially produced lot of the SoZo
® beverage. The
placebo consisted of a commercially available pear juice
that was freshly diluted 1:9 in water. All samples were
shaken well immediately prior to administration.
All study participants were informed about study
goals, study design and PRB features, and signed a con-
sent form prior to treatment. Study participants were
instructed to fast overnight and to avoid vigorous exer-
cise for 12 hours prior to participation. All study partici-
pants were routinely asked about how they were feeling
during the four hours of post-treatment, in part to iden-
tify subjects that might have been experiencing hypogly-
cemia, so as to avoid collection of data from subjects
affected by low blood glucose levels during this acute
study. Blood collection was performed by medical
laboratory scientists and phlebotomists. Blood was
drawn from the median cubital vein using Vacutainers
(Becton, Dickinson, Franklin Lakes, NJ). Sample collec-
tion was initiated immediately following informed con-
sent, and was performed on all participants at 7:00 AM
(T0).
Subjects were randomly given a single 3 oz. dose of
PRB or placebo immediately following the baseline
blood draw (T0). Subsequent blood samples were col-
lected at 1 (T60), 2 (T120), 3 (T180) and 4 (T240)
hours following consumption. Blood was centrifuged at
2000 g for 10 minutes and the serum was transferred to
fresh tubes for storage at -80°C. Participants were
required to remain inactive during the entirety of the
experiment and were allowed to drink only water. They
were encouraged to write down any subjective observa-
tions due to the treatment.
Blood samples of all subjects were analyzed for 8-iso-
PGF2-alpha levels using Cell BioLabs assay kit #STA337
(San Diego, CA). Due to the wide range of serum 8-iso-
PGF2-alpha levels determined at T0 and the desire to
study a population with low-grade inflammation, a sub-
group of subjects from both the treatment and placebo
groups (10 per group) with the highest 8-iso-PGF2-
alpha levels was utilized for further analysis. The sub-
group’s blood samples were assayed for additional bio-
markers, including advanced oxidation protein products
(AOPP) using Cell BioLabs assay kit #STA318 (San
Diego, CA); nitric oxide (NO) using Biomol/Enzo assay
kit #AK-136 (Plymouth Meeting, PA); hydroxyl radical
antioxidant capacity (HORAC) assay using Cell Biolabs,
assay kit #STA-346 (San Diego, CA) and C-reactive pro-
tein (CRP) using Hyphen BioMed assay kit #RK010A
(Neuville-Sur-Oise, France).
Statistical Analysis
Means were compared using a two-tailed Student’s t-test
(Microsoft Excel, Microsoft, Redmond, WA). Statistical
significance was set at p < 0.05.
3. Results
3.1 Phytochemical and Antioxidant Analysis Results
Levels of total polyphenols, total anthocyanins, total
proanthocyanidins, ellagic acid, and chlorogenic acid as
well as antioxidant capacities were determined and are
presented in Table 1.
3.2 Clinical Study Results
The characteristics of the study populations for the ran-
domized, double blind, placebo-controlled acute clinical
study were reasonably homogeneous are found in Table
Table 1 Phytochemical and antioxidant capacity analyses
of PRB sample per serving size (3.0 fl oz or 90 mL)
Compound/measurement Amount per serving
Total Anthocyanins 9 mg
Total Polyphenols 360 mg
Total Proanthocyanidins 170 mg
Chlorogenic Acid 225 mg
Ellagic Acid 3 mg
ORAC 10,292 μmole TE
HORAC 31,032 μmole TE
NORAC 643 μmole TE
SORAC 11,430 μmole TE
SOAC 7,457 μmole TE
Total ORAC 60,854 μmole TE
TE = Trolox equivalents
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jects are shown in Table 3. Subject number 22 was
unable to complete all of the blood sample collections,
and hence was not included. Subject 30’s samples were
disregarded due to hemolysis of blood. Biomarker ana-
lyses, performed on the 10 subjects from each group
with the highest 8-iso-PGF2-alpha levels, are shown in
Figures 1, 2, 3, 4 and 5; results are described below.
3.2.1 8-iso-PGF2-alpha
As presented in Figure 1, a single dose of PRB resulted
in a 40% average reduction of serum 8-iso-PGF2-alpha
during first 60 minutes, with depressed values continu-
ing for the next 3 hours. This was statistically significant
as compared to both the zero time point (p ≤ 0.001)
a n dt h ep l a c e b og r o u p( p<0 . 0 5 ) .T h ep l a c e b og r o u p
had a non-significant increase in 8-iso-PGF2-alpha after
treatment.
3.2.2 Advanced Oxidation Protein Products (AOPPs)
A ss h o w ni nF i g u r e2 ,s i n g l ed o s et r e a t m e n tw i t hP R B
reduced AOPP blood level by 39% during first 60 min.
The decrease was statistically significant (p < 0.05) com-
pared to T0. AOPP values returned to near baseline
during the following hours after treatment.
3.2.3 Nitric oxide (NO)
As presented in Figure 3, acute, single dose treatment
with PRB increased blood levels of total nitric oxide
slightly although the increase was not statistically signifi-
cant. The placebo group had a statistically significant
decrease of NO at T60, which continued to decrease
through T180.
3.2.4 C-reactive proteins (CRP)
Baseline blood levels of CRP were moderately high in all
study participants, with a mean of 20.6 ng/mL in PRB
group, and mean of 16.7 ng/mL in the placebo group. A
trend towards decreased CRP was seen after PRB
administration (Figure 4), but the decrease was not sta-
tistically significant. The PRB treatment mean change
from T0 for the average of the time points over the 4
hours post-treatment was just outside the significance
range (p = 0.07). Placebo had no significant effect on
CRP.
3.2.5 HORAC blood levels
PRB treatment led to significantly increased average
blood HORAC values at 1 hour and remained signifi-
cantly increased over the 4 hours; however, the placebo
treatment also produced increases at the T120 and
Table 2 Characteristics of study participants
Initial Subjects Subgroup Subjects
Mean Age in Years (SD) Mean BMI (SD) Females Males n Mean Age in Years (SD) Mean BMI (SD) Females Males n
PRB 48.63 (4.00) 29.47 (3.26) 8 8 16 49.3 (4.72) 30.08 (2.90) 4 6 10
Placebo 47.53 (3.09) 28.62 (2.67) 7 8 15 48.5 (3.30) 29.13 (2.51) 5 5 10
SD=standard deviation
Table 3 Serum 8-iso-PGF2-alpha levels at T0
Treatment Group Subject Number 8-iso-PGF2-alpha (pg/mL) Control Group Subject Number 8-iso-PGF2-alpha (pg/mL)
1 1431.2 17 310.9
2 323.7* 18 131.9*
3 946.8 19 1011.5
4 678.7 20 22.1*
5 974 21 1121
6 772.4 23 107*
7 770.9 24 818
8 330.2* 25 206.4*
9 728.4 26 1503
10 965.2 27 414.5
11 308.9* 28 356.4
12 756.9 29 373.4
13 1432.8 30 1190
1
14 255.2* 31 344.5
15 582.2* 32 294
16 728.4*
1subject data excluded due to hemolysis
*subjects excluded from subgroup analysis due to lowest 8-iso-PGF2-alpha levels
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increases were greater in the treatment group as com-
pared to the placebo group, differences between placebo
and PRB groups were not statistically significant.
3.2.6 Additional testing
Blood serum was also analyzed for general clinical
chemistry measurements at T0 and T240. Neither PRB
nor placebo adversely affected parameters such as ALT,
AST, glucose or LDH levels (data not shown).
No subjective observations were recorded that were
considered either positive or negative with regards to
the treatment or study design.
4. Discussion
Free radicals or reactive oxygen/nitrogen species may
play a major role in many diseases, such as cancer,
atherosclerosis, Alzheimer’s and the entire aging process
[35-38]. The most common reactive oxygen or nitrogen
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Figure 1 Effect of PBR on serum 8-iso-PGF2-alpha levels, expressed as pg/mL + SEM.* p≤ 0.001 as compared to T0 (paired T-test); and p
< 0.05 as compared to placebo (unpaired T-test).
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Figure 2 Effect of PBR on AOPP levels; expressed as nM/mL + SEM. * p < 0.05 as compared to T0 (paired T-test).
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Page 6 of 11species existing in the body are peroxyl (ROO), hydroxyl
(HO), hydrogen peroxide (H2O2), superoxide (O2
-), sing-
let oxygen (
1O2) and peroxynitrite (ONOO
-) [39]. As
shown in Table 1, PRB showed an especially high in
vitro antioxidant potential in the hydroxyl radical anti-
oxidant capacity assay.
The phenolic compounds that were found in high
concentrations in PRB (Table 1) are some of the most
widely distributed plant secondary products. The ability
of these compounds to act as antioxidants is well estab-
lished [40,41]. Additionally, calcium fructoborate, a
water-soluble boro-carbohydrate found most notably in
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Figure 3 Effect of PBR on NO levels; expressed as μmoles/L + SEM.
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Figure 4 Effect of PBR on serum CRP levels; expressed as ng/mL + SEM.
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Page 7 of 11certain fruits, nuts, vegetables and legumes [42-44], is a
component of PRB, and has been previously reported to
exhibit antioxidant and anti-inflammatory activity in
vitro [45,46].
Acute blood biomarker testing provides a relatively
quick and cost effective way to evaluate the potential
efficacy of natural products in humans, and has
mechanistic screening value. Acute changes in biomar-
ker values suggest that an orally ingested substance: a)
survives the chemistries of the gut and/or is converted
into active components in the gut, b) is absorbed into
the bloodstream, and c) is measurably bioactive, and
must work, at least partly, though rapidly accessed
mechanisms, rather than by mechanisms requiring repe-
titive dosing and/or cumulative effects.
The present study demonstrated that PRB has not
only antioxidant effects in vitro, but that a single intake
may impact measurements of serum biomarkers with
antioxidant and anti-inflammatory actions in subjects
with elevated BMI and 8-iso-PGF2-alpha levels. When
the initial evaluation of 8-iso-PGF2-alpha was per-
formed, it was noted that despite selecting for inclusion
of subjects with an elevated BMI as a way to investigate
subjects experiencing an elevated degree of inflamma-
tion and/or oxidation (obesity is linked to low-grade
inflammatory states) [47,48]; [49], the levels of serum 8-
iso-PGF2-alpha varied widely in subjects at T0 within
both experimental groups. Normal serum levels of 8-
iso-PGF2-alpha are considered to be 40-100 pg/mL
(STA-337-isoprostane-assay-kit). Higher plasma levels
are associated with a number of health problems such
as cardiovascular disease, diabetes, and inflammatory
and arthritic disorders [15,18-21,50]. Chu and colleagues
have shown that the plasma 8-iso-PGF2-alpha level in
aged rats is 30.6-fold higher than that of young rats,
reflecting the enhanced status of oxidative stress in aged
animals [51].
Hence, due to the exploratory nature of the pilot
s t u d ya n dt h ed e s i r et oo b s e r v ee f f e c t so ni n d i v i d u a l s
with elevated serum 8-iso-PGF2-alpha, biomarker analy-
sis in this study was performed on a post-hoc subgroup
of the ten subjects from each group with the highest 8-
iso-PGF2-alpha levels. The results of post-hoc analyses
are of interest and important for generating plausible
hypotheses of efficacy [52].
As presented, PRB had statistically significant effects
on blood levels of AOPP and 8-iso-PGF2-alpha during
the first 60 minutes after the treatment. Additionally,
there was a trend toward effects on NO and CRP levels.
Both placebo and PRB groups showed a statistically sig-
nificant increase in HORAC levels. These results suggest
that PRB is absorbed and acts quickly in fasting subjects,
and raises the possibility that repeated, regular intake
could produce effects that may exceed those observed
here, with unknown potential clinical benefits.
PRB showed a statistically significant effect of lowering
serum 8-iso-PGF2-alpha levels that was rather large; a
single intake resulted in a mean reduction of 40% in 60
minutes and an average of 42% over the next 4 hours.
This result suggests that the acute effect on plasma 8-
iso-PGF2-alpha is both rapid and sustained during first
4 hours after treatment, and justifies further studies
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Figure 5 Effect of PBR on HORAC levels; expressed as μM GAE/L + SEM. *p < 0.01 as compared to T0 by paired T-test.
Nemzer et al. Nutrition Journal 2011, 10:67
http://www.nutritionj.com/content/10/1/67
Page 8 of 11using specified 8-iso-PGF2-alpha levels as an inclusion
criterion, to both validate this result and explore related
effects, such as if PRB may reduce risk of cardiovascular
conditions and/or other health problems.
T h et i m ec o u r s eo fs p e c i f i cP R Ba c t i o n sw a sn o tc o n -
sistent across all tested markers. The PRB inhibitory
effect on AOPP was rather short compared to its effect
on PGF2-alpha; the 8-iso-PGF2-alpha effect persisted
for at least 4 hours after the treatment, while AOPP
readings tended to return to baseline between 1 and 4
hours. This result may be consistent with the literature,
as AOPPs are known to respond rapidly to changes
[22], although how rapidly they respond is unclear. It is
possible that repeated intakes of PRB would lower
AOPP readings for more prolonged periods. AOPPs are
pro-inflammatory mediators associated with a number
of inflammatory conditions [23,24], and also directly
impair HDL metabolism, and therefore could play a role
in cardiovascular disease development [53].
A number of publications have reported that increases
in nitric oxide (NO) levels are beneficial, especially for car-
diovascular health [54]. NO can be destroyed by reactive
oxygen species, and PRB has antioxidant properties [55].
The PRB-induced increase in NO concentrations was not
statistically significant, but the change was different over
placebo, as placebo caused NO values to decrease. One
possible explanation for the observed post-treatment NO
concentrations in the PRB group is that NO values can
increase and diminish throughout the day, and that PRB
may have prevented one of the NO declines [56,57].
The acute effect of PRB on CRP was not statistically
significant. However, the mean acute reduction of CRP at
T60 by nearly 5% is nonetheless surprising since blood
levels of this biomarker are considered to be rather stable
[58]. The placebo group showed a 2.2% increase in CRP
at the same time point. Future studies could investigate
the potential anti-inflammatory potential of repeated
intakes of PRB using CRP as a longer-term marker.
S i n c eP R Bw a sf o u n dt oh a v eah i g hH O R A Cr e a d i n g
during in vitro screening (Table 1), it was of interest to
determine whether ingested PRB could change HORAC
blood values in vivo in the clinical study. Hydroxyl radicals
play an important role in fatigue and functioning of mus-
cles, muscle respiratory metabolism, muscle inflammation,
Alzheimer’s disease and DNA damage in general [59-64].
Interestingly, some anti-inflammatory drugs work in part
by reducing blood levels of hydroxyl radicals [65].
A single PRB ingestion produced a strong mean rise in
HORAC values that was rapid and sustained. Surpris-
ingly, the placebo group also showed a rise in HORAC
values. Although the percent increase in the PRB group
over T0 exceeded that for placebo for all but the T120
time point (Table 4), the changes were not significantly
different between the two treatment groups.
T h eu n e x p e c t e dr i s ei ns e r u mH O R A Cv a l u e si nt h e
placebo group raises a question as to whether extended
fasting (up to 16 hours total, as was essentially experi-
enced by subjects by the end of the observation period)
may contribute to healthier antioxidant blood status.
Data on AOPP, another distinct antioxidant measure-
ment, did not show such a trend in the placebo group.
It is therefore possible that only certain types of antioxi-
dant markers change favorably due to extended fasting.
Further clinical studies would be required to test this
possibility.
When comparing average baseline values (T0) pre-
sented in Figures 1, 2, 3, 4 and 5 between placebo and
PRB groups, values of 8-iso-PGF2-alpha and HORAC
were statistically different in a manner that may be sig-
nificant. However, average values of AOPP and CRP
were not statistically different between the two experi-
mental groups at T0. Since subjects were randomly
assigned to each experimental group, this observation
was unexpected. A further study using a cross-over
design may clarify and substantiate further the results
and unexpected observations by allowing for within-sub-
ject analysis.
Conclusions
In conclusion, the collected data demonstrates the
potential utility of acute biomarker measurements for
evaluating antioxidant/anti-inflammatory effects of nat-
ural products such as PRB, and quantitatively shows
that a mixture of polyphenol-rich fruit and vegetable
components may work acutely on specific oxidative and
inflammatory markers in human blood through appar-
ently rapidly acting, though currently unidentified,
mechanisms. Results generated by this pilot study justify
additional, cross-over type clinical investigations of PRB
with narrower inclusion criteria to verify results and to
investigate more specific health conditions.
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